Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way.

Researchers at the Scripps Research Institute in San Diego and Vanderbilt University have discovered a “missing link” in the structure of a transmembrane receptor that could lead to new treatments for autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

Children with autism spectrum disorders have trouble integrating simultaneous information from their eyes and their ears--as if they experience the world like a badly-dubbed movie.

Vanderbilt University investigators for the first time have linked a non-inherited, de novo mutation in the dopamine transporter to autism spectrum disorder (ASD).

Several Vanderbilt researchers have collaborated with this year's Nobel Chemistry winners.

When discovering drugs for brain disorders, it’s important to test the candidates in multiple ways to avoid advancing those with restricted physiological effects.

Identification of brain regions involved in processing sights and sounds may offer insights into disorders like autism and dyslexia.